Skip to main content
2026 Prospectus
National Breast Cancer Awareness Month 2026 executive healthcare observance hero.

· Executive Brief

National Breast Cancer Awareness Month 2026

Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 32 min read

Leadership signal

Recognition becomes useful when leaders inspect the real route.

The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

Breast cancer awareness is a test of follow-through

Breast cancer touches nearly every part of a health system: screening programs, diagnostic imaging, primary care, surgery, oncology and the long years of survivorship that follow treatment. National data show real progress alongside unfinished work. Breast cancer mortality declined by 44% overall from 1989 to 2022, translating to 517,900 fewer breast cancer deaths, while incidence rose by 1% annually during 2012 to 2021.[9] That combination means more people moving through screening, diagnosis, treatment and long-term follow-up each year, and more handoffs for leaders to govern.

Progress has not been shared evenly. Black women have 38% higher breast cancer mortality than White women despite 5% lower incidence.[9] Yet a 2024 analysis of 1,742 similarly treated trial patients with triple-negative breast cancer found no racial differences in breast cancer outcomes.[8] When equal treatment goes with equal outcomes, attention turns to the parts of care that organizations control: access, timeliness, quality and coordination.

The operating risk sits between steps rather than inside any single department. In a trial across 44 primary care practices, only 22.9% of patients with overdue abnormal cancer screening results completed recommended follow-up within 120 days under usual care.[13] Time to surgery of 9 weeks or later after diagnosis was associated with worse overall survival than surgery within 4 weeks.[14] National Breast Cancer Awareness Month is a useful moment to ask who owns each of those intervals and how the organization knows when one has stalled.

The sections below summarize current peer-reviewed evidence on screening participation, follow-up after abnormal mammograms, time to diagnosis and treatment, patient navigation, disparities in outcomes and survivorship coordination. They sit beside the executive guidance already on this page, giving boards and operating leaders a shared factual base for choosing where to act first.

Current evidence

What the research shows about screening participation and follow-up

Screening participation looks stable at the population level but is eroding in specific groups. In national survey data covering 2,619,292 U.S. women from 2002 to 2022, mammography use showed nonsignificant biennial changes of −0.54% among women aged 40 to 49 and −0.16% among women aged 50 to 74.[1] Significant declines were observed among young women without health insurance (−1.54% per biennium), current smokers (−1.36%), unmarried women (−1.10%) and non-Hispanic White women (−0.58%).[1] An aggregate screening rate can therefore look steady while the organization loses the people least connected to care.

A steady screening program can also mask what happens after a recall. In a national breast imaging registry covering 2008 to 2021, follow-up was documented for 66.4% of 2,874,310 abnormal screening mammograms, and the overall median time to diagnostic evaluation was 9 days.[11] Of 318,977 recalls recommended for biopsy, 74.8% had a documented biopsy, and the overall median time from diagnostic evaluation to biopsy was 21 days.[11] Because the registry captured documented care, leaders should treat an undocumented result as both an information gap and a possible care gap.

The experience of a false alarm shapes whether people come back. In a cohort of 3,529,825 screening mammograms from 177 facilities among 1,053,672 women aged 40 to 73, 76.9% of women returned to screening after a true-negative result.[10] Return was 15.9 percentage points lower after a false-positive result with a short-interval follow-up recommendation and 10.0 percentage points lower after one with a biopsy recommendation.[10] Recall and biopsy experiences are therefore part of long-term screening retention, not only of a single diagnostic episode.

Closing the loop on abnormal results is achievable but not automatic. A cluster randomized trial in 44 primary care practices enrolled 11,980 patients with overdue abnormal cancer screening results.[13] Adjusted 120-day follow-up completion was 22.9% with usual care and 22.7% with electronic health record reminders alone.[13] Completion rose to 31.0% when reminders were paired with patient outreach and to 31.4% when navigation was added.[13] Breast results made up 8% of enrolled patients, or 1,005 people, and the investigators reported similar results across cancer types and levels of risk.[13] The pattern matters for any program that relies on clinician reminders as its main safeguard: an alert that no one acts on is a record of the gap, not a control for it.

Figure 1

Breast cancer follow-through: how many people complete the next step

Breast cancer follow-through: how many people complete the next stepPercent of people completing the next pathway step, as reported in each study (%). Values are copied from the cited studies [10], [11], [13]; none is estimated.0%25%50%75%100%Follow-up documented after an abnormalscreening mammogramFollow-up documented after an abnormal screening mammogram: 66.4% (source [11])66.4%[11]Biopsy documented when recommended afterrecallBiopsy documented when recommended after recall: 74.8% (source [11])74.8%[11]Returned to screening after a true-negative resultReturned to screening after a true-negative result: 76.9% (source [10])76.9%[10]Overdue abnormal screening resultsfollowed up within 120 days, usual careOverdue abnormal screening results followed up within 120 days, usual care: 22.9% (source [13])22.9%[13]Overdue abnormal screening resultsfollowed up within 120 days, remindersOverdue abnormal screening results followed up within 120 days, reminders plus outreach and navigation: 31.4% (source [13])31.4%[13]Source [11]Source [10]Source [13]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Percent of people completing the next pathway step, as reported in each study (%). Values are copied from the cited studies [10], [11], [13]; none is estimated.

Data note. The first three bars come from different studies, populations, years and definitions, so they are an indirect comparison; only the last two bars come from the same randomized trial and can be compared directly.

Limitation. Registry values reflect documented care only; the return-to-screening value describes women with true-negative results, not recalled women; the trial values pool four cancer types, of which breast results were 8%.

Figure data (5 rows)
Figure 1 data: Breast cancer follow-through: how many people complete the next step
MeasureValuePopulation, setting and year as reportedSource
Follow-up documented after an abnormal screening mammogram66.4%2,874,310 abnormal screening mammograms in a national U.S. breast imaging registry, 2008 to 2021[11]
Biopsy documented when recommended after recall74.8%318,977 recalls recommended for biopsy in the same registry, 2008 to 2021[11]
Returned to screening after a true-negative result76.9%Women aged 40 to 73 in a breast imaging cohort from 177 facilities; 3,529,825 screening mammograms, 2005 to 2017[10]
Overdue abnormal screening results followed up within 120 days, usual care22.9%Adjusted rate in the usual-care arm (n = 2,702) of a cluster randomized trial in 44 U.S. primary care practices; breast, cervical, colorectal and lung results; enrolled 2020 to 2021[13]
Overdue abnormal screening results followed up within 120 days, reminders plus outreach and navigation31.4%Adjusted rate in the reminders, outreach and navigation arm (n = 3,455) of the same trial[13]
A mammography technologist wipes down the screening unit before the first patient of the day.
Illustrative image. Follow-up was documented for 66.4% of abnormal screening mammograms in a national U.S. breast imaging registry.[11]

Continuum of care

Where the continuum breaks between diagnosis, treatment and survivorship

Each step after a recall depends on a handoff that someone must accept, and those handoffs perform differently across settings. In the national registry, Black, Hispanic and mixed or other race women waited longer for diagnostic evaluation.[11] Biopsy waits were also longer for older women and at rural and community hospital-affiliated facilities.[11] Where imaging, biopsy and surgical consultation sit in different services or organizations, leaders should expect more points at which a step can stall and should name one accountable owner for the whole interval.

The interval from diagnosis to treatment carries measurable risk. In a hospital registry analysis of 373,334 patients diagnosed from 2010 to 2014, surgery at 9 weeks or later was associated with worse overall survival than surgery within 4 weeks (hazard ratio 1.15).[14] The authors supported the use of 8 weeks or less as a quality metric for time to surgery.[14] That gives executives a published threshold for reviewing the diagnosis-to-treatment interval rather than an informal expectation.

The same analysis showed who is most likely to wait. Compared with surgery at 1 to 30 days, the odds of surgery at 61 to 74 days were 1.64 for patients aged 45 or younger and 2.13 for Medicaid patients.[14] For Medicaid patients, surgery after 74 days carried an odds ratio of 3.42.[14] The authors noted that time to surgery beyond 8 weeks may partly reflect disadvantaged social determinants of health.[14] That makes the treatment-start interval a natural place to direct navigation, financial counseling and scheduling support.

Coordination does not end when active treatment does. A survey followed 1,412 women diagnosed with breast cancer in 2014 and 2015 through registries in Georgia and Los Angeles, about six years later.[6] Survivorship care was oncologist-led for 57.2%, shared for 20.5% and primary care-led for 22.4%.[6] Primary care management of eight common survivorship issues averaged 11.4 on a 0 to 32 scale.[6] Most often discussed were medication management (50.1%), physical activity (49.1%) and chronic disease management (43.6%).[6]

Greater confidence in the primary care clinician’s ability to manage survivorship care was associated with primary care-led delivery and with more primary care management of survivorship issues.[6] The authors described primary care involvement as low more than five years after treatment and identified clinician confidence as a possible lever for shifting care.[6] Long-term follow-up therefore needs an explicit owner and a deliberate handoff, not an assumption that oncology or primary care has it.

Figure 3

Why the pathway breaks

Cause-and-effect diagram: People with an abnormal mammogram or a new breast cancer diagnosis do not reach timely diagnostic resolution, treatment start and coordinated survivorship careUnranked qualitative cause-and-effect diagram for the outcome in the box: People with an abnormal mammogram or a new breast cancer diagnosis do not reach timely diagnostic resolution, treatment start and coordinated survivorship care Causes are assembled from the cited literature [1], [3], [4], [5], [6], [7], [10], [11], [12], [13], [14], [15]; categories are not weighted and their order carries no meaning.People with an abnormalmammogram or a new breastcancer diagnosis do not reachtimely diagnostic resolution,treatment start andcoordinated survivorship carePeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • Breast radiologist, technologist and support staff shortages
  • Navigator time not directed to diagnostic follow-up and treatment start
  • Primary care clinicians less confident managing survivorship care

Process

  • Recall, biopsy and surgery steps owned by different services
  • Clinician reminders used without patient outreach
  • No named owner for survivorship follow-up between oncology and primary care

Technology

  • Follow-up completed elsewhere is not documented or visible
  • Reading workload not matched to screening volume
  • Overdue results tracked but not acted on

Environment

  • Longer waits at rural and community hospital-affiliated facilities
  • Anxiety around biopsy timing and results
  • Distrust shaped by prior interactions with medical systems
  • Employment, medication cost and medical bill burdens after treatment

Policy

  • Copay- and deductible-dominated plans with fewer follow-up imaging procedures
  • Declining mammography use among uninsured younger women
  • Medicaid status associated with longer time to surgery

Measurement

  • Aggregate screening rates hide declining subgroups
  • Follow-up and time to surgery not stratified by race, age, payer or facility
  • Return to screening after false-positive results not tracked

Unranked qualitative cause-and-effect diagram for the outcome in the box: People with an abnormal mammogram or a new breast cancer diagnosis do not reach timely diagnostic resolution, treatment start and coordinated survivorship care Causes are assembled from the cited literature [1], [3], [4], [5], [6], [7], [10], [11], [12], [13], [14], [15]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeopleBreast radiologist, technologist and support staff shortages; Navigator time not directed to diagnostic follow-up and treatment start; Primary care clinicians less confident managing survivorship care
ProcessRecall, biopsy and surgery steps owned by different services; Clinician reminders used without patient outreach; No named owner for survivorship follow-up between oncology and primary care
TechnologyFollow-up completed elsewhere is not documented or visible; Reading workload not matched to screening volume; Overdue results tracked but not acted on
EnvironmentLonger waits at rural and community hospital-affiliated facilities; Anxiety around biopsy timing and results; Distrust shaped by prior interactions with medical systems; Employment, medication cost and medical bill burdens after treatment
PolicyCopay- and deductible-dominated plans with fewer follow-up imaging procedures; Declining mammography use among uninsured younger women; Medicaid status associated with longer time to surgery
MeasurementAggregate screening rates hide declining subgroups; Follow-up and time to surgery not stratified by race, age, payer or facility; Return to screening after false-positive results not tracked

Access

Access after the screening visit depends on cost, timing and connection to care

Many access problems begin after a screening result rather than before it. Among 230,845 commercially insured women screened in 2016, coinsurance-dominated plans had the lowest mean out-of-pocket costs ($945) and deductible-dominated plans the highest ($1,186).[15] Women underwent significantly fewer subsequent breast imaging procedures in copay-dominated plans (24 fewer per 1,000 women) and deductible-dominated plans (16 fewer per 1,000 women) than in coinsurance-dominated plans.[15]

The authors concluded that, despite policies designed to remove financial barriers to breast cancer screening, significant financial barriers remain for women at risk of breast cancer.[15] For health systems, that places price transparency and financial counseling at the recall stage, before diagnostic imaging and biopsy, rather than only at the start of treatment. It also means access reviews should follow patients past the screening appointment into the diagnostic steps where cost-sharing applies.

Timing is another access lever, and it comes with trade-offs. In surveys of 974 women undergoing image-guided core needle breast biopsy at four sites, with a 65.6% response rate, 47.8% had been scheduled for a same-day biopsy.[12] Same-day biopsy was associated with better pre-biopsy overall satisfaction and satisfaction with wait time, but also with higher pre-biopsy and post-biopsy anxiety.[12] The authors suggested that reducing anxiety and improving communication could improve the experience of same-day biopsy.[12] Faster access works best when the conversation around it is designed with equal care.

Insurance status also appears in the participation trends. Among women aged 40 to 49 after the 2009 national screening recommendation change, significant declines in mammography use were observed among uninsured women (−2.39% per biennium) and Asian women (−2.45%).[1] Those patterns point to coverage, outreach and a usual source of care as access conditions that an awareness campaign cannot supply on its own. Leaders who want awareness to translate into completed care need to know which of those conditions their own population lacks.

Capacity is also part of access. In the national breast imaging staffing survey, practices with more sites and fewer breast imaging radiologists were more likely to report short-staffing.[3] A network that adds screening locations without matching reading, diagnostic imaging and biopsy capacity may simply move the queue from the screening appointment to the recall and biopsy steps. There it is harder for patients and leaders to see.

Executive guidance · System route

Map the path from first contact to verified follow-through.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. Listen
  2. Clarify entry
  3. Navigate across services
  4. Protect transitions
  5. Verify and learn

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. Listen

    Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.

  2. Clarify entry

    Publish a plain-language first step and identify who receives requests through each approved channel.

  3. Navigate across services

    Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.

  4. Protect transitions

    Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.

  5. Verify and learn

    Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.ListenClarify entryNavigate acrossservicesProtecttransitionsVerify and learnLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
ListenGather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entryPublish a plain-language first step and identify who receives requests through each approved channel.
Navigate across servicesMake the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.
Protect transitionsUse acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learnReview unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Equity and trust

Equity gaps run from screening participation to survival

Breast cancer outcomes differ sharply by race and ethnicity. Black women are less likely than White women to be diagnosed at a localized stage (58% versus 68%), and breast cancer mortality among American Indian and Alaska Native women has been unchanged since 1990.[9] Among women younger than 50, Asian American and Pacific Islander incidence rose from the second lowest in 2000 (57.4 per 100,000) to the highest in 2021 (86.3), alongside White women (86.4).[9]

Equal treatment may matter more than race in the survival gap. In a post-hoc analysis of the E5103 adjuvant chemotherapy trial, race was not associated with any disease event after adjustment, while larger tumor size and nodal involvement were.[8] National statistics show Black women have the lowest survival for every subtype and stage except localized disease.[9] Set side by side, these findings place equal access, timeliness and quality of care at the center of the equity question for health systems.

The same pattern appears in the operating steps that health systems run. In the national registry, documented follow-up after an abnormal screening mammogram was less common among younger, Black and American Indian women.[11] Documented biopsy was less common among women aged 80 and older, Black women and American Indian women.[11] After a false-positive result with a short-interval follow-up recommendation, Asian and Hispanic or Latinx women showed the largest declines in returning to screening, of 20 to 25 percentage points.[10] In the national participation trends, the post-2009 decline among women aged 40 to 49 was significant for Asian and uninsured women, while the change among non-Hispanic Black women (−0.59%) was not statistically significant.[1] Each of these findings describes a different step, which is why a single equity measure cannot show where a pathway is failing.

Lived experience helps explain why. In 28 focus groups with 134 Black, Latina and White women, three themes shaped screening: relationships with primary care providers, cancer’s potential impact on families and interactions with medical systems.[7] The authors found that cultural and structural factors appeared to influence screening approaches and that structural barriers may counteract culturally salient beliefs.[7] Trust, in this view, is earned through relationships and through removing the practical barriers that make a recommended step hard to complete. Stratified data on each step is how an organization shows that it is doing both.

A community health worker walks with two women from a partner van up the accessible ramp.
Illustrative image. Patient navigation increased breast cancer screening and follow-up across randomized trials.[4]

Human infrastructure

The people and tools that carry patients between steps

Breast imaging capacity is under strain. A national survey of breast imaging radiologists drew 309 responses, a 15.7% response rate.[3] Short-staffing was reported for breast radiologists by 79%, ultrasound technologists by 74%, mammography technologists by 70% and support staff by 66%.[3] Among respondents reporting a radiologist shortage, 92% attributed it to an insufficient number of radiologists and 67% to increased volume.[3] Academic practices were more likely to report short-staffing.[3]

Technology may relieve part of that pressure when it is tested rigorously. In a randomized trial of 105,934 women in a population-based screening program, artificial intelligence was used to triage examinations to single or double reading by radiologists and to provide detection support.[2] The interval cancer rate was 1.55 per 1,000 participants with AI support and 1.76 per 1,000 with standard double reading; sensitivity was 80.5% versus 73.8%, and specificity was 98.5% in both groups.[2] The authors reported that AI-supported screening achieved these results while also reducing screen-reading workload.[2]

Patient navigation is the most direct way to staff the transitions between steps. A meta-analysis of 42 randomized trials with 39,111 participants found that navigation increased breast cancer screening (risk ratio 1.50; 30 trials).[4] It also increased follow-up (risk ratio 1.23; 3 trials, 1,008 participants).[4] The predicted absolute difference was 13.8% higher breast cancer screening within one year of the intervention.[4] The small number of follow-up trials means navigation after an abnormal result is promising but less thoroughly tested than navigation into screening.

Navigation also needs to be matched to the problem it is meant to solve. In the primary care follow-up trial, completion was 31.4% with reminders, outreach and navigation versus 31.0% with reminders and outreach alone.[13] Where outreach already reaches patients, navigator time may be better spent on people facing cost, transportation, language or scheduling barriers. It may also be better spent on the diagnostic steps after a recall and on the interval between diagnosis and the start of treatment.

Workforce plans for breast pathways should therefore be built around specific transitions, including reading capacity, recall scheduling, biopsy access, navigation and survivorship handoffs, rather than around headcount alone. Each of those transitions relies on a different skill mix, and each fails in a different way when it is understaffed. Vacancy, backlog and overtime data for these roles belong in the same executive review as the completion measures they protect.

Executive guidance · Operating dashboard

Measure whether the operating route works as intended.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Entry-point clarityOwnership reliabilityNavigation continuityImprovement closure

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Entry-point clarity

Can people and staff identify the approved first step without searching across conflicting instructions?

Candidate local measure
Locally defined contact, routing, and repeat-contact signals by channel and service.

Executive guidance · Signal

Ownership reliability

Does a specific team accept each request and make its status visible?

Candidate local measure
Requests without an owner, aged work, transfers, and escalations using locally approved definitions.

Executive guidance · Signal

Navigation continuity

Where does ownership become unclear as people move among information, evaluation, services, and follow-through?

Candidate local measure
Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.

Executive guidance · Signal

Improvement closure

Does the organization correct recurring friction and report what changed?

Candidate local measure
Selected barriers, assigned actions, completion status, and post-change review.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Entry-point clarityOwner: Executive sponsor andoperational leadOwnership reliabilityOwner: Operational owner andparticipating teamsNavigation continuityOwner: Sending and receiving ownersImprovement closureOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Entry-point clarityExecutive sponsor and operational lead
Ownership reliabilityOperational owner and participating teams
Navigation continuitySending and receiving owners
Improvement closureImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Keep work owned when it crosses a boundary.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. Name the receiving service and confirm acceptance without promising a clinical determination or outcome.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Ask questions that connect intent, ownership, and results.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signal Executive question Candidate owner Suggested review point
Entry-point clarity Can people and staff identify the approved first step without searching across conflicting instructions? Executive sponsor and operational lead At campaign launch and close
Ownership reliability Does a specific team accept each request and make its status visible? Operational owner and participating teams At a locally defined cadence
Navigation continuity Where does ownership become unclear as people move among information, evaluation, services, and follow-through? Sending and receiving owners At a locally defined cadence
Improvement closure Does the organization correct recurring friction and report what changed? Improvement owner and executive sponsor Until action is verified

Figure 5

Control points for a reliable breast cancer follow-through pathway

Figure 5: Control points for a reliable breast cancer follow-through pathway
Control pointRisk if missingOwnerEvidence of control
Tracked closure of every abnormal screening mammogramRecalled patients never reach diagnostic evaluation or biopsy, with lower documented follow-up for some groupsBreast imaging medical director with ambulatory quality leadShare of recalls with documented diagnostic resolution and median days to evaluation and biopsy, stratified by race, age and facility
Patient outreach, not only clinician reminders, for overdue resultsOverdue results remain open despite electronic alertsPrimary care operations lead and navigation program managerShare of overdue abnormal results with follow-up completed within 120 days
Time-to-surgery review against an 8-week thresholdTreatment start drifts beyond the interval associated with worse survival, especially for patients with MedicaidSurgical oncology service line leader and cancer committeeShare of patients with surgery within 8 weeks of diagnosis, by payer and age
Financial counseling and price information at the recall stageCost-sharing deters diagnostic imaging after an abnormal screenRevenue cycle leader with patient financial servicesCounseling offered before diagnostic imaging and completion of recommended imaging by plan type
Recall and biopsy communication standardsFalse-positive results and anxiety reduce return to routine screeningBreast imaging director and patient experience leadReturn-to-screening rate after false-positive results and biopsy satisfaction and anxiety measures
Breast imaging staffing and reading capacity planRadiologist and technologist shortages lengthen waits and limit accessChief operating officer and radiology chairVacancy rates, reading backlog and appointment lead times reviewed quarterly
Named survivorship lead at the end of active treatmentLong-term care defaults to oncology with limited primary care involvementCancer center administrator and primary care medical directorDocumented survivorship lead and confirmed handoff for each patient completing treatment

Control points derived from the cited evidence [3], [6], [10], [11], [12], [13], [14], [15] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Communicating about screening, results and risk in ways that sustain trust

Public messages during National Breast Cancer Awareness Month are most useful when they support informed decisions and lead to services that can respond. The authors of the national mammography trend analysis called for clear, risk-based screening communication and targeted strategies to promote guideline-concordant decision-making, particularly for younger women.[1] That standard applies to campaign materials as much as to clinical conversations: messages should match the organization’s actual screening, scheduling and follow-up capacity.

Communication at the moment of a recall has long-term consequences. Return to screening fell after false-positive results, especially when short-interval follow-up or biopsy was recommended.[10] The recall conversation is therefore also a retention moment, and explaining what a benign outcome means and how routine screening resumes belongs in the result workflow rather than being left to chance.

Clinician communication also shapes the diagnostic experience directly. In the multisite biopsy survey, better radiologist-patient communication was associated with lower pre-biopsy anxiety and higher pre-biopsy satisfaction, and higher anxiety correlated with lower overall satisfaction.[12] Compared with White women, Black women reported lower post-biopsy anxiety but lower pre-biopsy satisfaction.[12] These findings support training and protected time for the conversations that happen between a recall and a diagnosis.

Messages also land differently across communities. Personal relationships with primary care providers were one of the themes that shaped how women approached screening.[7] That makes primary care teams a natural channel for observance messages, provided the referral and scheduling path behind them is ready. The focus group study concluded that communication interventions should be culturally adjusted and paired with structural changes.[7] A message that encourages screening while the diagnostic steps remain costly, slow or hard to reach can undermine the trust it was meant to build. That is why the access and equity findings above belong in communication planning.

Survivorship communication is the final link. Greater confidence in the primary care clinician’s ability to manage survivorship care was associated with primary care-led care.[6] In a small survey of 57 U.S. women aged 40 or older treated for cancer, nearly 80% saw the same oncologist at every appointment.[5] Yet over 63% no longer saw their primary care clinician from diagnosis.[5] Participants reported challenges with employment and returning to work (26%), affording medication (21%) and paying medical bills (15%).[5] The authors called for stronger patient-centered coordination and support.[5] Clear messages to patients and clinicians about who leads long-term follow-up, and when that changes, can support that confidence. Trust grows when what the organization says during the observance matches what patients experience at each step afterward.

A nurse navigator introduces a woman to an oncology nurse at a small consultation table.
Illustrative image. More than five years after initial treatment, 22.4% of breast cancer survivors in one study reported primary care-led survivorship care.[6]

Executive guidance · 90-day plan

Move from listening to a verified improvement in 90 days.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how National Breast Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how National Breast Cancer Awareness Month communicationsconnect to real entry points, owners, transitions, andescalation.Days 1–30: Map how National Breast Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Test one cross-service navigation handoff and correct thepoint where status or ownership becomes unclear.Days 31–60: Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how National Breast Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testTest one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Carry one accountable improvement beyond the campaign window.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Listen to the people closest to the route, assign one barrier, and verify the change.

Executive action kit · Month observance

Turn National Breast Cancer Awareness Month into accountable action.

Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Take it with you

Filed under

Chronic Disease and Specialty CarePublic Health and PreventionMonth

Leadership focus

Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, diagnostic navigation, support, and follow-through pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review whether language, transportation, cost, digital access, disability, geography, or trust changes a person’s ability to complete the locally approved route.

Five-minute briefing

Inspect the operating sequence

Listen with people using the pathway, caregivers, navigation teams, clinical services, and community partners. Find one a confusing entry point, unowned transition, or unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.

  1. Listen
  2. Clarify entry
  3. Navigate across services
  4. Protect transitions
  5. Verify and learn
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined contact, routing, and repeat-contact signals by channel and service.
  • Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
  • Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Patient Experience and Access Leaders
Staff communication template

During National Breast Cancer Awareness Month, our organization will connect awareness with a practical review of the information, diagnostic navigation, support, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

National Breast Cancer Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Trends in Mammography Use Among Women Aged 40 to 74 Years in the US, 2002-2022. JAMA Network Open. 2026;9(3):e263529. https://doi.org/10.1001/jamanetworkopen.2026.3529
  2. 2. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial. The Lancet. 2026;407(10527):505-514. https://doi.org/10.1016/S0140-6736(25)02464-X
  3. 3. Breast Imaging Staffing Shortages: Defining the Problem and Addressing Root Causes. Journal of Breast Imaging. 2025;7(6):676-684. https://doi.org/10.1093/jbi/wbaf031
  4. 4. Patient Navigation Services for Breast and Cervical Cancer Screening and Follow-Up: A Meta-Analysis. JAMA Internal Medicine. 2025;185(8):976-985. https://doi.org/10.1001/jamainternmed.2025.1590
  5. 5. Continuity of Cancer Care: Female Participants’ Report of Healthcare Experiences After Conclusion of Primary Treatment. Current Oncology. 2025;32(7):399. https://doi.org/10.3390/curroncol32070399
  6. 6. Oncology and Primary Care Involvement in Breast Cancer Survivorship Care More Than 5 Years After Initial Treatment. JCO Oncology Practice. 2025;21(6):791-800. https://doi.org/10.1200/OP-24-00620
  7. 7. Centering intersectional breast cancer screening experiences among black, Latina, and white women: a qualitative analysis. Frontiers in Public Health. 2024;12:1470032. https://doi.org/10.3389/fpubh.2024.1470032
  8. 8. Racial Disparities in Outcomes of Patients With Stage I-III Triple-Negative Breast Cancer After Adjuvant Chemotherapy: A Post-Hoc Analysis of the E5103 Randomized Trial. Breast Cancer Research and Treatment. 2024;206(1):185-193. https://doi.org/10.1007/s10549-024-07308-8
  9. 9. Breast cancer statistics 2024. CA: A Cancer Journal for Clinicians. 2024;74(6):477-495. https://doi.org/10.3322/caac.21863
  10. 10. Association Between False-Positive Results and Return to Screening Mammography in the Breast Cancer Surveillance Consortium Cohort. Annals of Internal Medicine. 2024;177(10):1297-1307. https://doi.org/10.7326/M24-0123
  11. 11. Rate and Timeliness of Diagnostic Evaluation and Biopsy After Recall From Screening Mammography in the National Mammography Database. Journal of the American College of Radiology. 2024;21(3):427-438. https://doi.org/10.1016/j.jacr.2023.09.002
  12. 12. Now or Later? Patient Satisfaction and Anxiety Among Women Undergoing Breast Biopsies Performed the Same Day as Recommended Versus a Later Day. Journal of the American College of Radiology. 2024;21(3):415-424. https://doi.org/10.1016/j.jacr.2023.07.028
  13. 13. A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial. JAMA. 2023;330(14):1348-1358. https://doi.org/10.1001/jama.2023.18755
  14. 14. Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery. JAMA Surgery. 2023;158(5):485-492. https://doi.org/10.1001/jamasurg.2022.8388
  15. 15. Patient Cost-Sharing and Utilization of Breast Cancer Diagnostic Imaging by Patients Undergoing Subsequent Testing After a Screening Mammogram. JAMA Network Open. 2023;6(3):e234893. https://doi.org/10.1001/jamanetworkopen.2023.4893

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
Breast cancer incidence and mortality trends, stage at diagnosis and racial and ethnic disparities[9]2024Executive openingNational descriptive statistics through 2021 to 2022; trends do not identify causes.
Racial differences in breast cancer outcomes among similarly treated patients[8]2024Equity and trustPost-hoc analysis of one adjuvant trial enrolling from 2007 to 2011, limited to 1,742 triple-negative patients with known self-reported race; median follow-up was 46 months.
Mammography use trends by age, insurance, smoking, marital status and race and ethnicity[1]2026Current evidenceSelf-reported national survey data on mammography in the past two years; biennial cycles from 2002 to 2022.
Documented follow-up and biopsy after recall, time intervals and variation by group and facility type[11]2024Current evidenceRegistry captures documented care at participating facilities from 2008 to 2021; follow-up done elsewhere may be missed.
False-positive results and return to routine screening[10]2024Current evidenceObservational cohort from 2005 to 2017; association rather than causation.
Multilevel intervention for overdue abnormal cancer screening results[13]2023Current evidenceThree health networks; breast results were 8% of enrolled patients and 83.3% of participants were White.
Time to surgery, overall survival and characteristics associated with delay[14]2023Continuum of careHospital-based registry data for diagnoses from 2010 to 2014; observational associations.
Oncology and primary care roles in survivorship care more than five years after treatment[6]2025Continuum of careSelf-reported survey of women from two regions diagnosed in 2014 and 2015; 60% response rate.
Cost-sharing and use of diagnostic imaging after screening[15]2023AccessCommercially insured women with claims from 2015 to 2017; findings do not cover Medicaid, Medicare or uninsured women.
Same-day versus later-day biopsy satisfaction, anxiety and communication[12]2024AccessCross-sectional survey at four sites from November 2020 to January 2022; self-reported outcomes.
Intersectional screening experiences, trust and structural barriers[7]2024Equity and trustQualitative focus groups; themes are not prevalence estimates.
Breast imaging staffing shortages and causes[3]2025Human infrastructureSurvey with a 15.7% response rate measuring perceived short-staffing.
AI-supported screening accuracy and reading workload[2]2026Human infrastructureSingle population-based screening program with double reading as the comparator; applicability to single-reading settings is uncertain.
Patient navigation for breast screening and follow-up[4] [13]2025, 2023Human infrastructureHigh heterogeneity for screening outcomes; only three trials for breast follow-up; the primary care trial pooled four cancer types.
Continuity of oncology and primary care after treatment and financial and employment burdens[5]2025Public communicationSmall survey (57 of 1,224 eligible participants completed it) of women with any cancer diagnosis; limited generalizability.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.